WallStSmart

Carlsmed, Inc. Common Stock (CARL)vsHinge Health, Inc. (HNGE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Hinge Health, Inc. generates 1045% more annual revenue ($646.34M vs $56.44M). CARL leads profitability with a -57.8% profit margin vs -78.9%. HNGE earns a higher WallStSmart Score of 36/100 (F).

CARL

Avoid

29

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 6/9Altman Z: 1.51

HNGE

Hold

36

out of 100

Grade: F

Growth: 7.3Profit: 3.5Value: 5.0Quality: 5.0
Piotroski: 3/9Altman Z: -2.69

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CARL2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
58.2%10/10

Revenue surging 58.2% year-over-year

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

HNGE2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
47.2%10/10

Revenue surging 47.2% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Areas to Watch

CARL4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Altman Z-ScoreHealth
1.514/10

Distress zone — elevated risk

Market CapQuality
$277.29M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-36.0%2/10

ROE of -36.0% — below average capital efficiency

HNGE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
43.4x2/10

Trading at 43.4x book value

Return on EquityProfitability
-197.2%2/10

ROE of -197.2% — below average capital efficiency

EPS GrowthGrowth
-68.4%2/10

Earnings declined 68.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : CARL

The strongest argument for CARL centers on Revenue Growth, Debt/Equity. Revenue growth of 58.2% demonstrates continued momentum.

Bull Case : HNGE

The strongest argument for HNGE centers on Revenue Growth, Debt/Equity. Revenue growth of 47.2% demonstrates continued momentum.

Bear Case : CARL

The primary concerns for CARL are EPS Growth, Altman Z-Score, Market Cap.

Bear Case : HNGE

The primary concerns for HNGE are Piotroski F-Score, Price/Book, Return on Equity.

Key Dynamics to Monitor

CARL is growing revenue faster at 58.2% — sustainability is the question.

HNGE generates stronger free cash flow (43M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HNGE scores higher overall (36/100 vs 29/100) and 47.2% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Carlsmed, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. The company is headquartered in Carlsbad, California.

Hinge Health, Inc.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Hinge Health, Inc. develops health care software for joint and muscle health. The company is headquartered in San Francisco, California.

Visit Website →

Want to dig deeper into these stocks?